Vipadenant, also known as BIIB014, CEB-4520, is a potent, selective and orally available adenosine A2A receptor antagonist under development for for Parkinson's disease. Vipadenant demonstrates strong oral activity in commonly used models of Parkinson's disease. Vipadenant has shown excellent preclinical pharmacokinetics and has successfully completed phase I clinical studies.
台州市科瑞生物技术有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
crene